HKSH Medical Group Strengthens Collaboration with United Imaging

Introducing Hong Kong’s First Total-Body PET/CT System to Strengthen “Dual-Tracer” in Nuclear Medicine and Advance Innovation in Cancer Theranostics

HONG KONG SAR – Media OutReach Newswire – 23 September 2026 – HKSH Medical Group (HKSH) has long been committed to advancing precision medicine. In the field of cancer diagnosis, HKSH actively introduces innovative technologies and promotes clinical research to support the most accurate clinical diagnosis and treatment planning, where nuclear medicine is an indispensable medical specialty in modern cancer diagnosis and treatment. To further expand its technological capabilities, HKSH Cancer Centre has introduced Hong Kong's first long axial total-body PET/CT system, developed by United Imaging Healthcare (United Imaging). The system enables highly sensitive whole-body dynamic imaging combining low radiation exposure, efficiency and high precision. In a single imaging examination, it can accurately track small early-stage cancer lesions and hidden metastatic cancer cells throughout the body, significantly enhancing diagnostic effectiveness and helping physicians formulate targeted precision treatment plans.

Mr. Wyman LI, Governor of The Li Shu Fan Medical Foundation, Chief Operating Officer of HKSH Medical Group and Director of Hong Kong Sanatorium & Hospital (2nd left), Mr. BAO Jun, President of United Imaging Healthcare (2nd right), Mr. XIA Jusong, President of International Business at United Imaging Healthcare (right), and Dr. Garrett HO, Head of Department of Nuclear Medicine and PET at HKSH (left), officiated at the launch ceremony of Hong Kong's first total-body PET/CT system.

Mr. Wyman LI, Governor of The Li Shu Fan Medical Foundation, Chief Operating Officer of HKSH Medical Group and Director of Hong Kong Sanatorium & Hospital, Mr. BAO Jun, President of United Imaging Healthcare, Mr. XIA Jusong, President of International Business at United Imaging Healthcare, and Dr. Garrett HO, Head of Department of Nuclear Medicine and PET at HKSH, officiated today at the launch ceremony for Hong Kong's first long-axial total-body PET/CT system. The ceremony marks the strengthened collaboration between HKSH and United Imaging, further advancing innovation in medical imaging technology and the development of higher clinical diagnostic standards across Greater China.

Mr. Wyman LI, Governor of The Li Shu Fan Medical Foundation, Chief Operating Officer of HKSH Medical Group and Director of Hong Kong Sanatorium & Hospital, said, "Precision cancer care is at the core of HKSH's development, while advanced diagnostic imaging is an indispensable component of precision medicine. HKSH established Asia's first clinical PET centre in 1999. Today, HKSH operates 5 medical cyclotrons and 3 radiopharmacy laboratories capable of producing more than 30 types of positron-emitting tracers and isotope-based medicines, making it one of the few cancer centres in the region with comprehensive nuclear medicine services."

With high expectations for the collaboration between HKSH and United Imaging in advancing nuclear medicine imaging, Mr. Wyman LI added, "Last year, HKSH and United Imaging entered into a strategic collaboration, through which HKSH helps optimise the application of United Imaging's CT systems with its extensive clinical experience. This year, we are deepening our collaboration by introducing Hong Kong's first total-body PET/CT system. The system overcomes the limitations of conventional scanning and helps detect early and hidden cancer lesions. This new generation of PET/CT scanners enable further integration of HKSH's extensive clinical experience with United Imaging's advanced research and development capabilities. Together, we aim to provide safer, more efficient and personalised cancer diagnosis and treatment for patients in Hong Kong and the Greater Bay Area. Looking ahead, we will continue to promote innovation in medical imaging and establish new standards for precision medicine."

Mr. Jun BAO, President of United Imaging Healthcare, said, "United Imaging has always believed that the value of medical imaging innovation lies in addressing real clinical needs and creating meaningful value for patients. Looking ahead, we look forward to working with HKSH to bring advanced molecular imaging technologies to more patients in Hong Kong."

The United Imaging uMI Panorama GS total-body PET/CT system's most significant breakthrough is its 148-centimetre ultra-long axial field of view. It enables the brain, heart, lungs, liver and other major organs to be imaged simultaneously in a single scan, overcoming the limitations of conventional PET systems, which generally provide a local scanning range of only 15 to 30 centimetres.

A single imaging examination can capture near-full-body images seamlessly, eliminating the need for patients to undergo multiple local scans and subsequent image stitching to track hidden metastatic lesions. The expanded detection range increases system sensitivity by up to 25 times. Its enhanced photon-detection capability allows the dose of injected tracer to be reduced, significantly lowering radiation exposure and providing a safer imaging exam option for radiation-sensitive patients, including paediatric patients. At the same time, high-definition dynamic imaging enables clinical teams to monitor tracer distribution, uptake and metabolic trajectory in real time. Combined with artificial intelligence-based denoising technology, the system further enhances cancer diagnostic performance. All these advantages together with much improved electronics and algorithms contribute to the capability of tracer dynamic studies. The addition of a time variable can resolve different phases of tracer interaction with the target organ or tumours.

Mr. Jusong XIA, President of International Business at United Imaging Healthcare, said, "Working with leading healthcare institutions around the world is an important part of United Imaging's international development. The introduction of Hong Kong's first long-axial PET/CT at HKSH reflects the deep integration of United Imaging's technological innovation with Hong Kong's clinical expertise, and demonstrates how advanced imaging technologies can be better integrated into different healthcare systems and clinical practice."

Advanced Hardware Combined with "Dual-Tracer Tracking" Reveals the Full Picture of Cancer

Accurate identification of cancer cells requires a high degree of integration of hardware and radiotracers. Although total-body PET/CT offers powerful detection capabilities, tracers are essential for guiding the imaging process. Conventional examinations may have limitations because different types of cancer cells at different stages have significantly different metabolic and receptor characteristics. As a result, using a single tracer may not reveal the full picture of cancerous lesions. In particular, some early-stage cancer cells may show limited uptake of conventional tracers, leading to less comprehensive examination results.

The launch of total-body PET/CT system is expected to further advance nuclear medicine technology in Hong Kong and the Greater Bay Area. It also marks a new milestone in the collaboration between HKSH and United Imaging, building on a strong foundation of cooperation. Looking ahead, HKSH will continue to play a leading role by combining the strengths of both parties to provide patients with more accurate and efficient cancer diagnosis.

1. Ho CL, Yu SC, Yeung DW. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med. 2003;44(2):213-221.
2. Ho CL, Chen S, Ho KM, et al. Dual-tracer PET/CT in renal angiomyolipoma and subtypes of renal cell carcinoma. Clin Nucl Med. 2012;37(11):1075-1082.
3. Ho CL, Chen S, Cheng T, Leung YL, Wong KK. Preliminary assessment of 11C-acetate and 18F-FDG PET/CT for the diagnosis and management of multiple myeloma. J Nucl Med. 2011;52(suppl 1):369.
4. Ho CL, Chen S, Leung YL, et al. 11C-acetate PET/CT for metabolic characterization of multiple myeloma: a comparative study with 18F-FDG PET/CT. J Nucl Med. 2014;55(5):749-752.

Hashtag: #HKSH

The issuer is solely responsible for the content of this announcement.

About HKSH Medical Group

Officially launched in September 2017, HKSH Medical Group promotes public health and advanced medicine through a multi-faceted, coordinated approach across clinical services, medical education, scientific research and public health education. Members of the Group, including Hong Kong Sanatorium & Hospital, HKSH Healthcare, HKSH Eastern Medical Centre, HKSH Cancer Centre and HKSH Institute for Innovation & Professional Development, are dedicated to offering top-quality holistic care to patients.

Established in 1922, Hong Kong Sanatorium & Hospital is one of the key members of HKSH Medical Group and a leading private hospital in Hong Kong. Living up to its motto of 'Quality in Service, Excellence in Care', the Hospital is committed to serving the public as well as promoting medical education and research.

For more information about HKSH Medical Group, please visit http://www.hksh.com.

** This press release is distributed by Media OutReach Newswire through automated distribution system, for which the client assumes full responsibility. **

Collaborating with Renowned Infectious Disease Specialist Prof. Zhang Wenhong’s Team to Drive the Application of Domestic AI Computing Power in Healthcare

HONG KONG SAR – Media OutReach Newswire – 23 September 2026 – Suanova Technology Limited ("Suanova"), a wholly-owned subsidiary of Yeebo (International Holdings) Limited ("Yeebo"; Stock Code: 00259.HK), recently participated in the inauguration ceremony of the "Suanova Hong Kong-Shanghai Joint Laboratory for AI in Healthcare" held in Shanghai. As a key supporter of the Joint Laboratory, Suanova will provide computing infrastructure, together with full-stack support services including data cleansing, underlying network deployment, and storage system construction, with the aim of advancing the deep integration of domestic computing power and the healthcare industry.

The Joint Laboratory is jointly established by Fudan University and The Hong Kong Polytechnic University, with a focus on strategic interdisciplinary AI research in the medical and healthcare sector. It is dedicated to promoting the application of AI technologies in medicine, clinical practice and public health. Prof. Zhou Lei, Vice President of Fudan University, and Prof. Wing-tak Wong, Deputy President and Provost of The Hong Kong Polytechnic University together unveiled the Joint Laboratory. Prof. Yang Hongxia, Executive Director of PolyU Academy for Artificial Intelligence (PAAI), and Prof. Zhang Wenhong, Head of the Institute of Infection and Health of Fudan University, signed the cooperation agreement on behalf of the two institutions. Mr. Douglas Fang, Chairman of Yeebo, and Ms. Li Liu, President of Fudan University Education Development Foundation, signed a donation agreement for the development of the Joint Laboratory. Mr. Daliang Chen, Chief Executive Officer of Suanova, attended the ceremony and delivered a speech.

Leading Experts at the Helm, Bridging World-Class Medical Research with Advanced AI

The convergence of AI and healthcare has emerged as one of the most important frontiers of global technological innovation. Shanghai is accelerating its development into a globally influential science and technology innovation hub, while Hong Kong is advancing its vision of becoming an international innovation and technology centre. The Joint Laboratory is strategically positioned at the intersection of two key national development regions: the Yangtze River Delta and the Greater Bay Area.

Fudan University possesses deep expertise in the fields of infectious diseases, clinical medicine and public health. Leveraging premier institutions such as the National Medical Center for Infectious Diseases and Huashan Hospital, the university provides abundant clinical scenarios and research resources for studies involving the surveillance and early warning of emerging and unexpected infectious diseases, AI-assisted diagnosis of complex infections, and the early identification of antimicrobial resistance risks. The Hong Kong Polytechnic University, through its PAAI Research Institute and Research Institute for Generative AI, possesses strong capabilities in frontier fields including generative AI and domain-specific large language models. Going forward, the two institutions will collaborate on research initiatives spanning generative AI, infectious disease studies, medical informatics, and bioinformatics, while also promoting the translation of research outcomes into real-world applications and industry adoption.

Prof. Zhang Wenhong, Head of the Institute of Infection and Health of Fudan University is one of the Joint Laboratory's academic leaders. Widely recognized as one of China's most influential experts in infectious diseases and public health, Professor Zhang has dedicated his career to the diagnosis and treatment of infectious diseases, the prevention and control of major epidemics, and the advancement of public health systems. He earns a strong reputation both within China and internationally. His team has long been engaged in infectious disease prevention and control, translational clinical medicine, and the advancement of public health systems, achieving a series of significant breakthroughs in disease control and public health studies. Prof. Zhang's participation in the establishment of the Joint Laboratory underscores the project's academic excellence and its potential impact on both medical research and clinical practice.

Focusing on the Frontier of AI-Driven Healthcare, Empowering Medical Innovation with Domestic Computing Power

The Joint Laboratory will focus on exploring a decentralized and domain-specific large model development pathway, enabling hospitals, research institutions, and eventually even individual households to deploy and own their own large AI models. By allowing users to harness the benefits of AI while safeguarding data privacy and sovereignty, this vision closely aligns with Suanova's mission of "enabling every organization to build its own AI capabilities faster, better, and more cost-effectively."

Mr. Douglas Fang, Chairman of Yeebo, said, "We have long been optimistic about the development prospects of domestic computing power and AI, and firmly believe that education, scientific research, and deep technology are fundamental pillars for long-term value creation. The true value of AI in healthcare lies not only in technological advancement, but also in its ability to address real-world clinical challenges. Breakthroughs in medical AI require the combined support of leading medical experts, rich clinical resources, and high-performance computing infrastructure. Through our support for Joint Laboratory, we hope to accelerate the application of cutting-edge AI technologies in solving real healthcare needs and ensure that scientific innovation ultimately delivers meaningful benefits to society."

Mr. Daliang Chen, CEO of Suanova, said, "Since entering the domestic computing power industry four years ago, Suanova has built Shanghai's earliest domestic computing cluster and one of the city's first domestic supernodes, while successfully enabling a wide range of applications on domestic computing infrastructure. In support of the Joint Laboratory, we will contribute far more than computing resources. Our support will encompass the full technology stack, including data cleansing, underlying network deployment, and storage system construction. By leveraging domestic computing power as a robust foundation, we aim to support the Joint Laboratory's long-term efforts to integrate cutting-edge AI model technologies with medical expertise, helping translate scientific innovation into meaningful advances in healthcare."

The establishment of the Joint Laboratory marks a significant milestone in Suanova's commitment to translating domestic computing power into impactful real-world applications. By drawing on the research strengths of Fudan University and The Hong Kong Polytechnic University, together with the deep collaboration between the teams led by Prof. Zhang Wenhong and Prof. Yang Hongxia, Suanova is confident that the Joint Laboratory will drive meaningful advancements in areas such as intelligent infectious disease prevention and control, AI-assisted diagnosis and treatment, and innovative drug discovery and development.

Hashtag: #Yeebo

The issuer is solely responsible for the content of this announcement.

About Yeebo (International Holdings) Limited

Founded in 1988, Yeebo (International Holdings) Limited is a diversified electronic component company with a well-established presence in the global market. The Company's core business spans flat panel displays, computing power and capacitors, serving a broad spectrum of industrial and consumer applications. Headquartered in Hong Kong, Yeebo operates its manufacturing operations primarily in the Guangdong and Jiangsu provinces, supporting a global sales network that ensures localized service and support for its international clientele.

In alignment with its long-term strategic vision, Yeebo is leveraging its robust operational foundation to expand into the Artificial Intelligence ("AI") compute and related sectors. This initiative reflects the Company's commitment to innovation and technological advancement, with the objective of positioning Yeebo as a leading and influential participant in the rapidly evolving AI industry across mainland China and Hong Kong.

About Suanova Technology Limited

Suanova, under Yeebo, is an innovative technology company focused on delivering independent, efficient, and accessible domestic AI computing services. Its business spans three core areas: computing power and cloud operations, computing technology development and computing industry investment. With branches in Hong Kong, Shanghai and Hangzhou, it provides customers with better localized services. It is committed to transforming complex AI infrastructure into simple, efficient, and cost‑effective services through continuous technological innovation, with the goal of becoming a leading "infrastructure operator" in the AI era.

** This press release is distributed by Media OutReach Newswire through automated distribution system, for which the client assumes full responsibility. **